Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TK 8001

Next Previous
Drug Profile

TK 8001

Alternative Names: Anti-MAGE-A1 T-cell therapy - T-knife; MAGE-A1-directed TCR-transduced autologous CD8+ T-cell therapy - T-Knife; T-1367; TK-8001

Latest Information Update: 21 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator T-Knife
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 05 Feb 2024 T-knife GmbH terminates phase I/II clinical trials in Solid tumours (In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in Germany, Spain, Netherlands, Belgium and the United Kingdom (IV), due to sponsor decision (NCT05430555) (EudraCT2021-004158-49)
  • 20 Dec 2023 T-Knife suspends a phase I/II IMAG1NE trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Netherlands, Spain, United Kingdom and Germany (IV), to allow review of current data (NCT05430555)
  • 01 Jun 2023 Pharmacodynamics data from preclinical studies in Solid tumours released by T-knife Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top